Global Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2024

The poly ADP-ribose polymerase (PARP) inhibitor market size has grown rapidly in recent years. It will grow from7.52 billion in 2023 to $8.39 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth observed in the historical period can be attributed to several factors, including increased investment in clinical research, regulatory approvals for new drugs, intensified market competition among pharmaceutical companies, the development of drug combinations for enhanced efficacy, and the advocacy efforts of patients and patient advocacy groups.

The poly ADP-ribose polymerase (PARP) inhibitor market size is expected to see rapid growth in the next few years. It will grow to $13.13 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. The forecast period's growth is expected to be fueled by factors such as expanded indications for treatments, the advancement of personalized medicine approaches, the development of biomarkers, considerations in health economics, and the increasing penetration into emerging markets. Key trends anticipated in the forecast period encompass the rise of precision medicine initiatives, advancements in immunotherapy, the development of targeted therapies, the integration of artificial intelligence into drug discovery processes, and the adoption of patient-centric healthcare models.

The uptick in ovarian cancer cases is anticipated to be a driving force behind the expansion of the poly ADP-ribose polymerase (PARP) inhibitor market. Ovarian cancer, a malignancy affecting one or both ovaries, is influenced by factors such as genetic predisposition, aging demographics, environmental exposures, and hormonal imbalances. Poly ADP-Ribose Polymerase (PARP) Inhibitors serve as a vital component in ovarian cancer therapy, targeting DNA repair mechanisms, especially in patients harboring BRCA mutations, thereby inducing synthetic lethality and augmenting tumor cell demise. For instance, data from the World Ovarian Cancer Coalition in February 2022 revealed that ovarian cancer affected 3.13 million women globally in 2020, with projections indicating a 42% surge to reach 4.4 million by 2040. Furthermore, ovarian cancer-related deaths are anticipated to climb by 51% over the same period, rising from 2.07 million in 2020 to 3.13 million in 2040. Consequently, the escalating prevalence of ovarian cancer acts as a catalyst for the growth of the poly ADP-ribose polymerase (PARP) inhibitor market.

Leading players in the poly ADP-ribose polymerase (PARP) inhibitor market are focusing on the development of generic PARP inhibitors, tailored to cater to cancer patients with specific genetic mutations, thus offering personalized treatment modalities. Generic PARP inhibitors function by inhibiting the activity of the enzyme poly ADP-ribose polymerase (PARP). For example, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Olaparib under the IBYRA brand in March 2024. This PARP inhibitor targets specific genetic mutations prevalent in breast, ovarian, prostate, and pancreatic cancers, providing a customized and efficacious treatment regimen. Particularly advantageous for patients with HRD-positive or BRACA mutations, Olaparib aids in postponing disease progression, thereby enhancing patient outcomes.

In June 2023, Ariceum Therapeutics GmbH, a Germany-based radiopharmaceutical company, acquired Theragnostics Ltd. for $41.5 million. This strategic acquisition bolstered Ariceum Therapeutics' radiopharmaceutical portfolio, granting access to novel PARP inhibitor radiation therapies. Theragnostics Ltd., a UK-based biotechnology company, specializes in the development of radio-labeled PARP inhibitors for both diagnostic and therapeutic applications in tumor management.

Major companies operating in the Poly ADP-ribose polymerase (PARP) inhibitor market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Merck KGaA, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Genentech Inc., BioMarin Pharmaceutical Inc., Seattle Genetics Inc., Medivation Inc., Myriad Genetics Inc., PharmaMar S.A., Clovis Oncology, Nektar Therapeutics, Loxo Oncology Inc., Tolero Pharmaceuticals Inc., Everest Pharmaceuticals, Verastem Inc.

North America was the largest region in the poly ADP-ribose polymerase (PARP) inhibitor market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the Poly ADP-ribose polymerase (PARP) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Poly ADP-ribose polymerase (PARP) inhibitors are a category of pharmacological agents that function by inhibiting the enzyme PARP, crucial for DNA repair processes. By blocking PARP, these inhibitors effectively target cancers with deficiencies in other DNA repair pathways, thereby preventing cancer cells from repairing damaged DNA and ultimately leading to their demise.

The primary drug types of PARP inhibitors include talazoparib, veliparib, olaparib, and others. Talazoparib, for instance, is a potent PARP inhibitor utilized in cancer therapy, disrupting DNA repair mechanisms within cancer cells. These drugs are distributed through various channels such as hospital pharmacies, online pharmacies, retail pharmacies, among others. They have demonstrated efficacy in treating ovarian cancer, breast cancer, and other malignancies, and are utilized by various end users including hospitals, homecare facilities, specialty clinics, and others.

The poly ADP-ribose polymerase (PARP) inhibitor market research report is one of a series of new reports that provides poly ADP-ribose polymerase (PARP) inhibitor market statistics, including poly ADP-ribose polymerase (PARP) inhibitor industry global market size, regional shares, competitors with a poly ADP-ribose polymerase (PARP) inhibitor market share, detailed poly ADP-ribose polymerase (PARP) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the poly ADP-ribose polymerase (PARP) inhibitor industry. This poly ADP-ribose polymerase (PARP) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The poly ADP-ribose polymerase (PARP) inhibitor market consists of revenues earned by entities by providing services such as diagnostic tests, clinical trials, consulting services, and patient support programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The poly ADP-ribose polymerase (PARP) inhibitor market also includes sales of test kits, laboratory equipment, imaging systems, sample processing instruments, reagents, and chemicals. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.